Nebulized thiocyanate improves lung infection outcomes in mice

British Journal of Pharmacology

Volumn 169, Issue 5, 2013, Pages 1166-1177

  Chandler, J D ^a,c   Min, E ^a   Huang, J ^a   Nichols, D P ^a   Day, B J ^a,b,c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

cystic fibrosis; inflammation; inhaled antioxidant; innate immunity; lung infection; neutrophil; Pseudomonas aeruginosa; thiocyanate

Indexed keywords

THIOCYANATE; ANTIOXIDANT; CYTOKINE; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; OXIDIZING AGENT; PEROXIDASE; PYOCYANINE; THIOCYANIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LUNG FLUID; LUNG INFECTION; MALE; MOUSE; NEBULIZATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; ANIMAL; BLOOD; C57BL MOUSE; CELL COUNT; CELL LINE; CYTOLOGY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; LUNG LAVAGE; METABOLISM; MICROBIOLOGY; NEBULIZER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; ANIMALS; ANTIOXIDANTS; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CELL LINE; CYTOKINES; HUMANS; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; LUNG DISEASES; MALE; MICE, INBRED C57BL; NEBULIZERS AND VAPORIZERS; OXIDANTS; PEROXIDASE; PEROXIDASES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYOCYANINE; THIOCYANATES;

EID: 84879015771     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12206     Document Type: Article

References (61)

1. Arnhold J, Monani E, Furtmuller PG, Zederbauer M, Casella L, Obinger C, (2006). Kinetics and thermadynamics of halide and nitrite oxidation by mammalian heme peroxidases. Eur J Inorg Chem 2006: 3801-3811.
2. Ashby MT, Carlson AC, Scott MJ, (2004). Redox buffering of hypochlorous acid by thiocyanate in physiologic fluids. J Am Chem Soc 126: 15976-15977.
3. Bishop C, Hudson VM, Hilton SC, Wilde C, (2005). A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 127: 308-317.
4. Chandler JD, Day BJ, (2012). THIOCYANATE: a potentially useful therapeutic agent with host defense and antioxidant properties. Biochem Pharmacol 84: 1381-1387.
5. Conner GE, Wijkstrom-Frei C, Randell SH, Fernandez VE, Salathe M, (2007). The lactoperoxidase system links anion transport to host defense in cystic fibrosis. FEBS Lett 581: 271-278.
6. van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ, (1997). Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 327 (Pt 2): 487-492.
7. Davies JC, Bilton D, (2009). Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 54: 628-640.
8. Davis PB, (2006). Cystic fibrosis since 1938. Am J Respir Crit Care Med 173: 475-482.
9. Day BJ, van Heeckeren AM, Min E, Velsor LW, (2004). Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72: 2045-2051.
10. Denning GM, Wollenweber LA, Railsback MA, Cox CD, Stoll LL, Britigan BE, (1998). Pseudomonas pyocyanin increases interleukin-8 expression by human airway epithelial cells. Infect Immun 66: 5777-5784.
11. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF, (1996). Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 21: 77-83.
12. Fahy JV, Boushey HA, Lazarus SC, Mauger EA, Cherniack RM, Chinchilli VM, et al. (2001). Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med 163: 1470-1475.
13. Fragoso MA, Fernandez V, Forteza R, Randell SH, Salathe M, Conner GE, (2004). Transcellular thiocyanate transport by human airway epithelia. J Physiol 561 (Pt 1): 183-194.
14. Gao L, Kim KJ, Yankaskas JR, Forman HJ, (1999). Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 277 (1 Pt 1): L113-L118.
15. Garcia MA, Yang N, Quinton PM, (2009). Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 119: 2613-2622.
16. Geiszt M, Witta J, Baffi J, Lekstrom K, Leto TL, (2003). Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J 17: 1502-1504.
17. Gould NS, Gauthier S, Kariya CT, Min E, Huang J, Day BJ, (2010). Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res 11: 119.
18. Gould NS, Min E, Day BJ, (2011). Macropinocytosis of extracellular glutathione ameliorates tumor necrosis factor alpha release in activated macrophages. PLoS ONE 6: e25704.
19. Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, et al. (2004). Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 169: 822-828.
20. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T, (1997). Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 100: 2810-2815.
21. Henke MO, John G, Rheineck C, Chillappagari S, Naehrlich L, Rubin BK, (2011). Serine proteases degrade airway mucins in cystic fibrosis. Infect Immun 79: 3438-3444.
22. Ioannidou E, Siempos II, Falagas ME, (2007). Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 60: 1216-1226.
23. Kanthakumar K, Taylor G, Tsang KW, Cundell DR, Rutman A, Smith S, et al. (1993). Mechanisms of action of Pseudomonas aeruginosa pyocyanin on human ciliary beat in vitro. Infect Immun 61: 2848-2853.
24. Kariya C, Chu HW, Huang J, Leitner H, Martin RJ, Day BJ, (2008). Mycoplasma pneumoniae infection and environmental tobacco smoke inhibit lung glutathione adaptive responses and increase oxidative stress. Infect Immun 76: 4455-4462.
25. Klamt F, Shacter E, (2005). Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage. J Biol Chem 280: 21346-21352.
26. 2 system. Oral Microbiol Immunol 7: 315-320.
27. Leung AM, Lamar A, He X, Braverman LE, Pearce EN, (2011). Iodine status and thyroid function of Boston-area vegetarians and vegans. J Clin Endocrinol Metab 96: E1303-E1307.
28. Lorentzen D, Durairaj L, Pezzulo AA, Nakano Y, Launspach J, Stoltz DA, et al. (2011). Concentration of the antibacterial precursor thiocyanate in cystic fibrosis airway secretions. Free Radic Biol Med 50: 1144-1150.
29. Lyczak JB, Cannon CL, Pier GB, (2002). Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15: 194-222.
30. Majewska E, Kasielski M, Luczynski R, Bartosz G, Bialasiewicz P, Nowak D, (2004). Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respir Med 98: 669-676.
31. Marshall VM, Reiter B, (1980). Comparison of the antibacterial activity of the hypothiocyanite anion towards Streptococcus lactis and Escherichia coli. J Gen Microbiol 120: 513-516.
32. Meotti FC, Jameson GN, Turner R, Harwood DT, Stockwell S, Rees MD, et al. (2011). Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J Biol Chem 286: 12901-12911.
33. Meyer KC, Zimmerman J, (1993). Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 121: 654-661.
34. Mikola H, Waris M, Tenovuo J, (1995). Inhibition of herpes simplex virus type 1, respiratory syncytial virus and echovirus type 11 by peroxidase-generated hypothiocyanite. Antiviral Res 26: 161-171.
35. Minarowski L, Sands D, Minarowska A, Karwowska A, Sulewska A, Gacko M, et al. (2008). Thiocyanate concentration in saliva of cystic fibrosis patients. Folia Histochem Cytobiol 46: 245-246.
36. Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCray PB, Jr, Nauseef WM, et al. (2007). A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 175: 174-183.
37. Nagahara N, Okazaki T, Nishino T, (1995). Cytosolic mercaptopyruvate sulfurtransferase is evolutionarily related to mitochondrial rhodanese. Striking similarity in active site amino acid sequence and the increase in the mercaptopyruvate sulfurtransferase activity of rhodanese by site-directed mutagenesis. J Biol Chem 270: 16230-16235.
38. Nagy P, Jameson GN, Winterbourn CC, (2009). Kinetics and mechanisms of the reaction of hypothiocyanous acid with 5-thio-2-nitrobenzoic acid and reduced glutathione. Chem Res Toxicol 22: 1833-1840.
39. Nash EF, Stephenson A, Ratjen F, Tullis E, (2009). Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev (1): CD007168.
40. O'Malley YQ, Reszka KJ, Spitz DR, Denning GM, Britigan BE, (2004). Pseudomonas aeruginosa pyocyanin directly oxidizes glutathione and decreases its levels in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 287: L94-103.
41. Pattison DI, Davies MJ, Hawkins CL, (2012). Reactions and reactivity of myeloperoxidase-derived oxidants: differential biological effects of hypochlorous and hypothiocyanous acids. Free Radic Res 46: 975-995.
42. Pedemonte N, Caci E, Sondo E, Caputo A, Rhoden K, Pfeffer U, et al. (2007). Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels. J Immunol 178: 5144-5153.
43. Quinton PM, (1983). Chloride impermeability in cystic fibrosis. Nature 301: 421-422.
44. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG, (2011). Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 183: 1517-1523.
45. Seear M, Hui H, Magee F, Bohn D, Cutz E, (1997). Bronchial casts in children: a proposed classification based on nine cases and a review of the literature. Am J Respir Crit Care Med 155: 364-370.
46. Sorensen RU, Klinger JD, Cash HA, Chase PA, Dearborn DG, (1983). In vitro inhibition of lymphocyte proliferation by Pseudomonas aeruginosa phenazine pigments. Infect Immun 41: 321-330.
47. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC, (2011). The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 184: 252-258.
48. Thomas EL, (1981). Lactoperoxidase-catalyzed oxidation of thiocyanate: equilibria between oxidized forms of thiocyanate. Biochemistry 20: 3273-3280.
49. Thomas EL, Fishman M, (1986). Oxidation of chloride and thiocyanate by isolated leukocytes. J Biol Chem 261: 9694-9702.
50. Thomas EL, Milligan TW, Joyner RE, Jefferson MM, (1994). Antibacterial activity of hydrogen peroxide and the lactoperoxidase-hydrogen peroxide-thiocyanate system against oral streptococci. Infect Immun 62: 529-535.
51. Velsor LW, van Heeckeren A, Day BJ, (2001). Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 281: L31-L38.
52. Wagner BA, Reszka KJ, McCormick ML, Britigan BE, Evig CB, Burns CP, (2004). Role of thiocyanate, bromide and hypobromous acid in hydrogen peroxide-induced apoptosis. Free Radic Res 38: 167-175.
53. Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, et al. (2005). Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73: 3693-3701.
54. Wark P, McDonald VM, (2009). Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev (2): CD001506.
55. Westley J, (1981). Thiosulfate: cyanide sulfurtransferase (rhodanese). Methods Enzymol 77: 285-291.
56. Wijkstrom-Frei C, El-Chemaly S, Ali-Rachedi R, Gerson C, Cobas MA, Forteza R, et al. (2003). Lactoperoxidase and human airway host defense. Am J Respir Cell Mol Biol 29: 206-212.
57. Wilson AM, Leigh R, Hargreave FE, Pizzichini MM, Pizzichini E, (2006). Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease. COPD 3: 89-93.
58. Winterbourn CC, Brennan SO, (1997). Characterization of the oxidation products of the reaction between reduced glutathione and hypochlorous acid. Biochem J 326 (Pt 1): 87-92.
59. Wu W, Chen Y, Hazen SL, (1999). Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem 274: 25933-25944.
60. Xu Y, Szep S, Lu Z, (2009). The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc Natl Acad Sci U S A 106: 20515-20519.
61. Xulu BA, Ashby MT, (2010). Small molecular, macromolecular, and cellular chloramines react with thiocyanate to give the human defense factor hypothiocyanite. Biochemistry 49: 2068-2074.